Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by targeting of anagen hair follicles by the host immune system resulting in varying degrees of hair loss. Topical…
For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…
Pharmacotherapy for adult asthma has two main goals: address underlying airway inflammation and promote bronchodilation. Two types of therapy are used to achieve these goals—maintenance therapy (…
MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus, eczema, and, in some cases, disrupted sleep and poor quality of life. Topical agents (e.g.,…
Hydroxychloroquine, corticosteroids, and conventional immunosuppressants are the mainstay of treatment for systemic lupus erythematosus (SLE), a chronic, complex autoimmune disease affecting…
MARKET OUTLOOK Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis (UC), whereas tumor necrosis factor-alpha (TNF-α)…
Metformin and the sulfonylureas are the most heavily prescribed drugs in T2D and dominate the early lines of therapy prior to disease progression, which requires insulin replacement. The emergence…
Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA) and the only other oral targeted therapy besides Celgene’s PDE-4 inhibitor, Otezla, approved for this indication…
Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA) and the only other oral targeted therapy besides Celgene’s PDE-4 inhibitor, Otezla, approved for this indication…
Allergic rhinitis is a chronic immunoglobulin E-mediated respiratory response to environmental allergens. It is typically treated with intranasal corticosteroids, followed by antihistamines, mast…
Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after that of Pfizer’s Jak inhibitor, Xeljanz (…
Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after that of Pfizer’s Jak inhibitor, Xeljanz (…
As the term implies, levodopa-induced dyskinesia (LID) is a complication of chronic use of levodopa, the gold standard of Parkinson’s disease (PD) treatment. Surveyed neurologists estimate that…
As the term implies, levodopa-induced dyskinesia (LID) is a complication of chronic use of levodopa, the gold standard of Parkinson’s disease (PD) treatment. Surveyed neurologists estimate that…